476 related articles for article (PubMed ID: 10569747)
1. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
[TBL] [Abstract][Full Text] [Related]
2. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
[TBL] [Abstract][Full Text] [Related]
3. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
[TBL] [Abstract][Full Text] [Related]
5. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
[TBL] [Abstract][Full Text] [Related]
7. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
[TBL] [Abstract][Full Text] [Related]
8. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.
Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Kaper JB; Levine MM
J Infect Dis; 1992 Oct; 166(4):837-41. PubMed ID: 1527420
[TBL] [Abstract][Full Text] [Related]
9. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
10. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
[TBL] [Abstract][Full Text] [Related]
11. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
[TBL] [Abstract][Full Text] [Related]
14. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
[TBL] [Abstract][Full Text] [Related]
16. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111.
Tacket CO; Kotloff KL; Losonsky G; Nataro JP; Michalski J; Kaper JB; Edelman R; Levine MM
Am J Trop Med Hyg; 1997 May; 56(5):533-7. PubMed ID: 9180604
[TBL] [Abstract][Full Text] [Related]
17. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.
Chen WH; Greenberg RN; Pasetti MF; Livio S; Lock M; Gurwith M; Levine MM
Clin Vaccine Immunol; 2014 Jan; 21(1):66-73. PubMed ID: 24173028
[TBL] [Abstract][Full Text] [Related]
20. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.
Taylor DN; Sanchez JL; Castro JM; Lebron C; Parrado CM; Johnson DE; Tacket CO; Losonsky GA; Wasserman SS; Levine MM; Cryz SJ
Infect Immun; 1999 Apr; 67(4):2030-4. PubMed ID: 10085055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
